Frontline Treatment Options Available for Patients With CLL
Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.
Jennifer Woyach, MD, an associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer CenterJames, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia (CLL).
There are a number of options in the first-line setting for patients with CLL, Woyach says. In terms of targeted therapies, ibrutinib (Imbruvica) can be used on its own as a single agent and most often is. However, acalabrutinib (Calquence), another BTK inhibitor, can be used with or without Obinutuzumab (Gazyva). There is also data on venetoclax (Venclexta) in combination with obinutuzumab.
Chemoimmunotherapy options are still considered, such as the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. FCR is considered especially for younger patients with IGVH-mutant CLL. Bendamustine/rituximab and chlorambucil/obinutuzumab are also still available, but Woyach says there are not a lot of scenarios where these would be used now.
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
January 22nd 2025The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
